OncoMatch/Clinical Trials/NCT03534713
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread
Is NCT03534713 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Carboplatin and Paclitaxel for cervical cancer tnm staging regional lymph nodes (n).
Treatment: Carboplatin · Paclitaxel · Cisplatin — The main objective of this study is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves overall survival rates compared to standard therapy alone in women with cervical cancer with paraaortic lymph node involvement. Women in the experimental arm will receive neoadjuvant chemotherapy with carboplatin and paclitaxel every 21 days during 3 cycles followed by standard therapy with extended field external radiation therapy and concomitant chemotherapy. Women in the control arm will receive standard therapy with extended field external radiation therapy and concomitant chemotherapy. 310 patients will be recruited during 4.5 years, with 3 years of follow up period.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IVA (International Federation of Gynecology and Obstetrics)
Excluded: Stage IVB
Stage International Federation of Gynecology and Obstetrics IB1 to IVA at diagnosis with para-aortic lymph node involvement; Stage Federation of Gynecology and Obstetrics IVB at diagnosis [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Lab requirements
Blood counts
Platelet count > 100x10^9/l and Absolute neutrophil count > 1.5X10^9/l
Kidney function
creatinine clearance ≥60 mL/min
Liver function
bilirubin <1.5 times normal and Serum Glutamooxaloacetate Transferase < 3 times normal
Cardiac function
Cardiovascular pathology New York Heart Association II or more [excluded]
Adequate renal function (creatinine clearance ≥60 mL/min); Adequate hepatic function (bilirubin <1.5 times normal and Serum Glutamooxaloacetate Transferase < 3 times normal); Adequate hematopoietic function Platelet count > 100x10 9/l and Absolute neutrophil count > 1.5X10 9/l); Cardiovascular pathology New York Heart Association II or more [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify